Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns "Buy" Rating from Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Chardan Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $300.00 price target on the biopharmaceutical company's stock. Chardan Capital's target price would indicate a potential upside of 21.58% from the company's current price.

Several other analysts also recently weighed in on ALNY. Wolfe Research downgraded Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday, November 12th. StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, January 9th. Needham & Company LLC restated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. Finally, Barclays raised their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $304.26.

Alnylam Pharmaceuticals Trading Up 4.1 %

Shares of ALNY traded up $9.65 during trading hours on Wednesday, hitting $246.75. 1,178,627 shares of the stock traded hands, compared to its average volume of 731,883. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The business has a fifty day moving average of $254.30 and a 200-day moving average of $262.42. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $31.94 billion, a PE ratio of -113.71 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insiders Place Their Bets

In related news, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,986 shares of company stock worth $20,397,849 over the last ninety days. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Jennison Associates LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $61,160,000. Strategic Financial Concepts LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $41,529,000. Los Angeles Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock worth $37,684,000 after buying an additional 135,829 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock worth $67,464,000 after buying an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock valued at $4,687,000 after acquiring an additional 2,285 shares during the period. Institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.